Treatment outcomes of pregnant women with drug resistant tuberculosis in Uganda: a retrospective review of 18 cases

Int J Infect Dis. 2021 Feb 18:S1201-9712(21)00118-1. doi: 10.1016/j.ijid.2021.02.032. Online ahead of print.


BACKGROUND: There is a dearth of reports on drug resistant tuberculosis (DRTB) treatment outcomes among pregnant women in TB/HIV high burdened countries. We report treatment outcomes of 18 pregnant women with DRTB in Uganda.

METHODS: We reviewed charts of individuals who received DRTB treatment in Uganda across 16 DRTB treatment sites. We included all women who were pregnant during DRTB treatment and had a treatment outcome documented between 2013 and 2019.

RESULTS: There were 18 pregnant women with a mean age (SD) of 27.5 (5.2) years, of whom 8 (44.4%) were HIV co-infected. Among these women, 12 (66.7%) had primary DRTB and 8 (44.4%) had multidrug resistant TB. Levofloxacin, Pyrazinamide, Cycloserine and Kanamycin were the most (>78%) used drugs in the treatment regimen and the mean (SD) treatment duration was 17.6 (7.5) months. Elevated liver enzymes (81.8%, n =11) and hearing loss (33.3%, n=15) were the most frequently encountered drug adverse events. Treatment success was observed among 15 (83.3%), 2 (11.1%) were lost to follow up and 1(5.6%) died.

CONCLUSION: The treatment success among pregnant women with DRTB in Uganda was high despite a high prevalence of HIV co-infection.

PMID:33610787 | DOI:10.1016/j.ijid.2021.02.032